Draximage MAA Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to prevalence of pulmonary disorders, adoption of nuclear imaging techniques, hospital diagnostic expansion, need for precise lung assessment, advancements in radiotracers.

The growth in the forecast period can be attributed to growth in respiratory disease burden, expansion of diagnostic imaging centers, improved gamma camera technology, rising early diagnosis focus, healthcare investment growth. Major trends in the forecast period include rising use of nuclear medicine imaging, expansion of lung function diagnostics, growing demand for v/q scans, advancements in radiopharmaceuticals, strengthening of hospital imaging services.

The rising incidence of lung cancer is expected to drive the growth of the Draximage MAA market in the coming years. Lung cancer is characterized by abnormal and uncontrolled cell growth in the lungs, which can spread to other parts of the body. The increasing prevalence of lung cancer is attributed to factors such as ongoing smoking habits, exposure to environmental pollutants like air pollution and secondhand smoke, occupational hazards including asbestos and radon, and an aging population. Draximage MAA supports lung cancer management as a radiopharmaceutical used in positron emission tomography (PET) imaging, assisting in diagnosis, staging, and monitoring treatment responses. This enables more accurate assessments and improved patient management strategies. For example, in January 2024, the American Cancer Society reported approximately 234,580 new lung cancer cases in the U.S., including 116,310 men and 118,270 women, along with 125,070 deaths, comprising 65,790 men and 59,280 women, highlighting slightly higher incidence in women but greater mortality in men. Therefore, the rising incidence of lung cancer is driving the growth of the Draximage MAA market.

The expanding geriatric population is also significantly contributing to the growth of the Draximage MAA market. The geriatric population typically includes individuals aged 65 years and older, who often have age-related health challenges. This population is increasing due to the aging global population, improved healthcare, and advancements in medical treatments that have extended life expectancy. Draximage MAA benefits the geriatric population by providing a radiopharmaceutical used in medical imaging to assess pulmonary function, detect conditions such as pulmonary embolisms, and monitor respiratory health. Accurate imaging is especially crucial for older adults, who may have multiple comorbidities and require precise diagnosis for effective treatment planning. For instance, in January 2024, the Population Reference Bureau reported that the population of Americans aged 65 and older is projected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase, with their share of the total population rising from 17% to 23% during the same period. Consequently, the growing geriatric population is driving the growth of the Draximage MAA market.

The increasing demand for medical imaging is also expected to propel the growth of the Draximage MAA market. Medical imaging involves techniques that produce visual representations of the body’s internal structures for diagnostic and therapeutic purposes. This demand is driven by factors including an aging population, prevalence of chronic diseases, improved healthcare infrastructure, and a shift toward minimally invasive procedures. Draximage MAA supports medical imaging by providing a radiopharmaceutical used in scintigraphy to visualize and assess pulmonary function, enabling enhanced accuracy in detecting abnormalities such as pulmonary embolisms and evaluating lung conditions, which aids in precise diagnosis and treatment planning. For example, in May 2023, the National Health Service reported that MRI activities referred by general practitioners in England increased from 8,695 in January 2022 to 8,745 in January 2023. Additionally, there were 43.4 million imaging tests conducted in England during the 12 months from February 2022 to January 2023. Therefore, the rising demand for medical imaging is driving the growth of the Draximage MAA market.

Major companies operating in the draximage maa market are Jubilant Draximage Inc.

North America was the largest region in the draximage MAA market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the draximage maa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the draximage maa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the draximage maa market by increasing costs for radioisotope sourcing, specialized packaging, and nuclear compliance equipment. These impacts have influenced hospital imaging departments and radiopharmacy services, especially in regions reliant on imported isotopes. Europe and asia pacific face higher sensitivity. However, tariffs have supported regional radiopharmaceutical production and improved long term diagnostic supply stability.

The draximage maa market research report is one of a series of new reports that provides draximage maa market statistics, including draximage maa industry global market size, regional shares, competitors with a draximage maa market share, detailed draximage maa market segments, market trends and opportunities, and any further data you may need to thrive in the draximage maa industry. This draximage maa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Draximage MAA is a radiopharmaceutical used in nuclear medicine for lung imaging. It contains macro-aggregated albumin (MAA) labeled with technetium-99m, allowing ventilation/perfusion (V/Q) lung scans to assess pulmonary function. The radiolabeled particles are injected and tracked with a gamma camera to evaluate lung function and identify abnormalities.

The main indications for Draximage MAA are lymphatic mapping and sentinel lymph node biopsy. Lymphatic mapping with Draximage MAA helps locate lymph nodes draining specific areas, supporting cancer diagnosis and guiding surgical planning by detecting potential cancer spread. It is distributed through hospital pharmacies, radiopharmacy services, and outpatient surgical centers, and used by hospitals, clinics, ambulatory care, and home care providers.

The draximage MAA market consists of sales of draximage MAA with human serum albumin and draximage MAA radiolabeled. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.